losartan has been researched along with Prostatic Neoplasms in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is an angiotensin II receptor (AT-II-R) blocker that is widely used by human for blood pressure regulation." | 1.43 | Losartan sensitizes selectively prostate cancer cell to ionizing radiation. ( Ghasemi, A; Hosseinimehr, SJ; Pourfallah, TA; Rafiei, A; Yazdannejat, H, 2016) |
| "Compound 4 can also inhibit the prostate cancer in vitro and in vivo." | 1.38 | Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects. ( Chen, ZL; Da, YJ; Liang, LS; Nie, YY; Xin, T; Yan, YJ; Ye, Y; Yuan, WD, 2012) |
| "Changes in the migration potential of prostate cancer cells were investigated using Wound Healing Test and a Transwell Migration Chamber with a 3 μm pore size." | 1.38 | Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. ( Domińska, K; Lachowicz-Ochędalska, A; Ochędalski, T; Piastowska-Ciesielska, AW, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Da, YJ | 2 |
| Yuan, WD | 1 |
| Xin, T | 1 |
| Nie, YY | 1 |
| Ye, Y | 1 |
| Yan, YJ | 2 |
| Liang, LS | 1 |
| Chen, ZL | 2 |
| Scott-Emuakpor, J | 1 |
| Allot, E | 1 |
| Johnson, SA | 1 |
| Howard, LE | 1 |
| Macias, E | 1 |
| Freedland, SJ | 1 |
| Gurley, SB | 1 |
| Zheng, HL | 1 |
| Zhu, WB | 1 |
| Wu, D | 1 |
| Bian, J | 1 |
| Yazdannejat, H | 1 |
| Hosseinimehr, SJ | 1 |
| Ghasemi, A | 1 |
| Pourfallah, TA | 1 |
| Rafiei, A | 1 |
| Bose, SK | 1 |
| Gibson, W | 1 |
| Giri, S | 1 |
| Nath, N | 1 |
| Donald, CD | 1 |
| Balink, H | 1 |
| Hemmelder, MH | 1 |
| de Graaf, W | 1 |
| Grond, J | 1 |
| Domińska, K | 1 |
| Piastowska-Ciesielska, AW | 1 |
| Lachowicz-Ochędalska, A | 1 |
| Ochędalski, T | 1 |
| Guimond, MO | 1 |
| Battista, MC | 1 |
| Nikjouitavabi, F | 1 |
| Carmel, M | 1 |
| Barres, V | 1 |
| Doueik, AA | 1 |
| Fazli, L | 1 |
| Gleave, M | 1 |
| Sabbagh, R | 1 |
| Gallo-Payet, N | 1 |
8 other studies available for losartan and Prostatic Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antineoplastic Agents; Cell Line | 2012 |
Angiotensin receptor signaling and prostate tumor growth in mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Losartan; Male; | 2017 |
Synthesis and biological evaluation of a new angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antineoplastic Agents; Blood Pre | 2014 |
Losartan sensitizes selectively prostate cancer cell to ionizing radiation.
Topics: Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Losartan; Male; Prostatic Ne | 2016 |
Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Ce | 2009 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che | 2011 |
Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation.
Topics: Angiotensin II; Angiotensin III; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Prolif | 2012 |
Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Cell Proliferation; Humans; Losartan; Male; Prostate; Prost | 2013 |